Differential Screening Service
Differential screening is an important part of biomarker research. Rigorous screening experiment design and sensitive sample analysis can help screen out biomarkers that are conducive to clinical transformation. Due to the complex composition of biological samples, the initial screening of biomarkers is a difficult part. As an expert in the field of biomarker services, Creative BioMart Biomarker has an experienced expert team and technical team, as well as a variety of advanced technical platforms that can be used for differential screening of biomarkers. We can help customers to customize the differential screening scheme according to the research needs of customers.
Biomarkers can specifically and sensitively reflect the state of the disease, and are used in the early screening, diagnosis, course monitoring, staging, prognosis and treatment response evaluation of various diseases. For clinical applications, ideal biomarkers can be clearly related to specific diseases or disease states, and can be used to distinguish similar physiological conditions. At the same time, the method to obtain such biomarkers should be convenient, from standard biological sources, such as serum and urine. In addition, ideal biomarkers can be quickly, easily, and accurately detected by existing detection technologies. Although some biomarkers have been found to be used as indicators of diseases or disease states, there is still a need to find new biomarkers to further promote the sensitivity and specificity of disease screening, thereby promoting the early diagnosis of diseases. Differential screening is an important means to find new biomarkers, usually through biotechnology analysis of differential expression between normal control samples and experimental samples to achieve the purpose of biomarker screening. With the advancement of biotechnology, not only can traditional biotechnologies be used for differential screening of biomarkers, the development of omics technology has also brought a broader development space for the discovery of new biomarkers. For example, differential expression analysis of serum glycoproteins by proteomics technology is used to screen new biomarkers for hepatocellular carcinoma. Omics technology has the advantages of high throughput and automation, enabling multiple markers to be screened at one time. The advancement of science has brought a variety of different analysis technologies to the field of biomarkers, which can provide different information for differential screening, and increase the chance of discovering new biomarkers, as well as help biomarkers move to clinical applications faster.
Figure 1. Workflow for urinary protein biomarker discovery (Duangkumpha, et al. 2019)
Optional Specimen Type
Serum, plasma, urine, CSF, whole blood, platelets, PBMC, cell lysates, tissue culture media, cultured cells, biopsy.
Optional Sample Category
DNA, RNA, protein/polypeptide, glycan, hormone
Optional Screening Methods
Our Advantages
- Multiple biomarker analysis technology platforms
- Optional high-throughput screening platform
- Experienced technical team
- Strict and standard experimental operation
- Provide complete experimental data and detailed professional analysis reports
- High quality and more efficient custom services
- Short service cycle and more competitive prices
Workflow of Custom Biomarker Service at Creative BioMart Biomarker
At Creative BioMart Biomarker, we provide customers with high-quality custom biomarker service related to differential screening, and our expert team can customize scientific and rigorous experimental programs as soon as possible according to customer research needs and sample types. Our technical team has many years of experience in biomarker analysis and has been strictly controlling each process in the screening to ensure that customers are provided with accurate, precise, and repeatable screening results. If you are seeking related services, Creative BioMart Biomarker may be your ideal choice, please feel free to contact us for more information.
References:
- Duangkumpha, K.; et al. Urine proteomics study reveals potential biomarkers for the differential diagnosis of cholangiocarcinoma and periductal fibrosis. PLOS One. 2019,14(8): e0221024.
- Gao, H. J.; et al. Quantitative proteomic analysis for high-throughput screening of differential glycoproteins in hepatocellular carcinoma serum. Ann Transl Med. 2015, 12(3): 246-254.
